ACR Alpine Capital Research LLC Increases Stock Holdings in Johnson & Johnson $JNJ

ACR Alpine Capital Research LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 0.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,228,942 shares of the company’s stock after buying an additional 2,383 shares during the quarter. Johnson & Johnson comprises approximately 6.1% of ACR Alpine Capital Research LLC’s holdings, making the stock its 9th biggest position. ACR Alpine Capital Research LLC owned approximately 0.09% of Johnson & Johnson worth $340,471,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in JNJ. GFG Capital LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $35,000. Stone House Investment Management LLC acquired a new position in Johnson & Johnson during the first quarter worth approximately $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson during the first quarter worth approximately $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on JNJ shares. Royal Bank Of Canada restated an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a research note on Friday, October 10th. Cowen restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. HSBC upped their price target on shares of Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Barclays raised their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Finally, Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $190.31 on Tuesday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The company’s 50 day moving average price is $182.54 and its two-hundred day moving average price is $166.65. The firm has a market cap of $458.50 billion, a PE ratio of 18.37, a PEG ratio of 2.24 and a beta of 0.40. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.